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Abstract
Recently, the intervention calculus when the DAG is absent (IDA) method was developed to estimate
lower bounds of causal effects from observational high-dimensional data. Originally it was introduced to
assess the effect of baseline biomarkers which do not vary over time. However, in many clinical settings,
measurements of biomarkers are repeated at fixed time points during treatment exposure and, therefore, this
method need to be extended. The purpose of this paper is then to extend the first step of the IDA, the Peter
Clarks (PC)-algorithm, to a time-dependent exposure in the context of a binary outcome. We generalised
the so-called “PC-algorithm” for taking into account the chronological order of repeated measurements of
the exposure and propose to apply the IDA with our new version, the chronologically ordered PC-algorithm
(COPC-algorithm). The extension includes Firth’s correction. A simulation study has been performed before
applying the method for estimating causal effects of time-dependent immunological biomarkers on toxicity,
death and progression in patients with metastatic melanoma. The simulation study showed that the completed
partially directed acyclic graphs (CPDAGs) obtained using COPC-algorithm were structurally closer to the
true CPDAG than CPDAGs obtained using PC-algorithm. Also, causal effects were more accurate when
they were estimated based on CPDAGs obtained using COPC-algorithm. Moreover, CPDAGs obtained by
COPC-algorithm allowed removing non-chronologic arrows with a variable measured at a time t pointing
to a variable measured at a time t′ where t′ < t. Bidirected edges were less present in CPDAGs obtained
with the COPC-algorithm, supporting the fact that there was less variability in causal effects estimated from
these CPDAGs. In the example, a threshold of the per comparison error rate of 0.5% led to the selection
of an interpretable set of biomarkers. Conclusions The COPC-algorithm provided CPDAGs that keep the
chronological structure present in the data and thus allowed to estimate lower bounds of the causal effect of
time-dependent immunological biomarkers on early toxicity, premature death and progression.
1 Background
The Intervention calculus when the directed acyclic graph (DAG) is absent (IDA) method was recently
developed to estimate lower bound of total causal effects from observational data in high-dimensional settings
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[1]. It was originally introduced to evaluate the effect of time-fixed exposure (gene expression). This method is
a combination of Peter Clarks (PC)-algorithm [2] and Pearl’s do calculus [3]. The PC-algorithm is a constraint
based method for causal structure learning, meaning that it learns the causal structure based on the conditional
dependencies of the observational distribution. The output of the PC-algorithm results in a CPDAG (completed
partially DAG) that encodes conditional dependencies of the data in a class of DAGs (Directed acyclic graphs)
called Markov Equivalent. Then, based on the DAGs in the Markov Equivalence Class, causal effects are
estimated using Pearl’s do calculus [3] (see section Computation of the causal effects). However, in many
clinical settings, time-dependent biomarker values under treatment or changes in biomarkers from baseline are
of interest. If the true DAG was known, the commonly used marginal structural model (MSM) approach could
applied to estimate causal effects in the case of time-dependent covariates and outcome [4, 5]. In our setting,
the true DAG being unknown, causal effects could not be identified using MSM.
In the 2010s, new anti-cancer treatments targeting immune checkpoints have been introduced: the wave
of these immunotherapies began with the anti CTLA-4 treatment which showed a survival benefit in patients
with metastatic melanoma [6, 7]. More recently, promising results in lung and kidney cancers have also been
obtained [8]. Nevertheless, only a subgroup of patients seem to benefit from this treatment: about 20% of
patients with metastatic melanoma treated with ipilimumab were long-term survivors (3 years) [9]. Moreover,
immune related toxicity such as colitis occurs in 8 to 22% of treated patients [10]. The goal of immunotherapy
is to amplify the immune system response against cancer cells. Thus, one can observe the evolution of the
treatment by looking at the immune system. Predictive and/or prognostic markers are ideally validated through
clinical trials including randomized studies, which are the gold standard [11, 12]. Before being evaluated in
randomized trial, candidate immunological biomarkers can be identified from high-dimensional data, collected
in an observational or non-randomized setting.
Our objective was to develop methods to identify the causal effects of time-dependent exposures on a binary
endpoint in a high-dimensional setting, with an application of time-dependent immunological biomarkers in a
non-randomized prospective study in oncology. . However, the PC-algorithm has never been applied on data
measured repeatedly at a fixed time points, and the chronological order among data is not respected when using
PC-algorithm. The first step was then to find the true CPDAG by extending the PC-algorithm to chronologically
ordered measures and then to estimate robust causal effects based on the CPDAG estimated using our version of
the PC-algorithm. To ensure the accuracy and the efficiency of our method, we made a simulation study where
we compared the CPDAGs’ structure obtained using PC-algorithm and our method. Then we compared the
estimation of true causal effects calculated based on CPDAGs obtained from both methods. Due to collinearity
among time-dependent biomarkers, we added for the first time the Firth’s correction while estimating causal
effects to avoid instability of the maximum likelihood estimates. After the simulation study, we applied both
PC-algorithm and our method to real dataset of time-dependent immunological biomarkers.
2 Material and methods
2.1 Graph definitions and notations
Let G(N,E) be a graph consisting of nodes N and edges E. Nodes represent random variables N =
{X1, . . . , Xp} and edges represent the links between them. An edge can be either directed Xi → Xj(in
this case, Xi is a parent of Xj and Xj is a descendant of Xi) or undirected Xi − Xj . A graph with only
undirected edges is said to be an undirected graph whereas a directed graph is made of only directed edges. A
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partially directed graph contains both directed and undirected edges. Two nodes are said to be adjacent if they
are connected by an edge (either directed or undirected). A path is a sequence of nodes in which all pairs are
adjacent. A path can be either open or closed. A path is open when there is no collision between two arrows
pointing to the same node on the path (i.e. the path from Xi to Xm in (1) is open).
Xi → Xj → Xk → Xm ← Xl (1)
A path is closed when there is a collision between two arrows which point to the same node of the path,
this variable is a collider (i.e, the path from Xi to Xi in (1) is closed). We denote Xk as a descendent
of Xi (and Xi an ancestor of Xk) if there is a path that starts from Xi and ends to Xk by following the
direction of the arrows (1). We also denote pa(Xi, G) as the parents of Xi in G by the set of variables
pointing to Xi. A graph is called acyclic when no path starts and ends at the same node. A graph which
is acyclic and has directed edges is called a directed acyclic graph (DAG). A DAG is complete or sta-
tistical when all pairs of nodes are adjacent, whereas a DAG is causal when all common causes of any
variable are on the graph, i.e. any parent is a cause of its descendants. Therefore, a causal DAG is informative
whereas a complete DAG is non-informative because a lack of arrow means an absence of a direct causal effect.
A graph encodes (conditional) independence relationships through the concept of d-separation [13]. If
two nodes are d-separated by a set of nodes, then the variables corresponding to the nodes are conditionally
independent given this set of variables. The set of these given variables is then called separation set S. Multiple
DAGs can be compatible with a same set of underlying conditional independences. Let a skeleton be the
graph obtained by removing all arrowheads from the DAG and the v-structures a subgraph of 3 nodes filling
two conditions: 1) both arrows are not pointed on Xj(Xj is not a collider) and 2) where Xi and Xj are not
adjacent.
The DAGs Xi → Xj → Xk, Xi ← Xj ← Xk and Xi ← Xj → Xk in which the two conditions hold
belong to the same Markov equivalence class and are called Markov equivalent. A whole equivalence class
can be summarised in a graph that has the same skeleton and includes the directed arrows of all DAGs in
the equivalence class. Edges which are directed differently across the DAGs in the equivalence class are
represented with bidirected arrows (or simply edges). This graph with both undirected and directed edges is
called a Completed Partially DAG (CPDAG).
2.2 Causal effect estimation in high dimensional settings
2.2.1 IDA
When the relationships between variables are not oriented, the DAG cannot be identified. With many vari-
ables in a high-dimensional setting, it is not possible to determine which nodes are ancestors and which are
descendants. The only possible initial graph that can be drawn based on high-dimensional data is a complete
undirected graph which is non-informative as in Figure 1. The intervention calculus when the DAG is absent
(IDA) method has been introduced to determine the CPDAG from the observational data and to estimate lower
bounds of the absolute values of the total causal effects in the case where all variables (including outcome) are
continuous [1]; and has been extended to the case where all variables are binary [14]. The first objective of
the IDA is to estimate the CPDAG and its Markov equivalence class that contain the true causal DAG from the
observational data by using a causal learning algorithm such as the PC-algorithm [2]. Then the intervention
calculus [3, 15] is used on the m DAGsj of the Markov equivalence class j = 1, . . . ,m, to estimate the p×m
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matrix θ of causal effects θij of each covariate Xi(i = 1, . . . , p) on Y .
Figure 1: A complete undirected graph.
However, estimating the true causal effect is impossible when a unique DAG is not identifiable. To deter-
mine whether or not a covariate has a potential causal effect, the minimum absolute causal effect of a covariate
is defined as βˆi = minj(|θˆi,j |). Then a ranking of covariates’ causal effects is made based on these lower
bounds, where βi1 is the lower bound of the covariate i with the rank 1:
βˆi1 ≥ βˆi2 ≥ . . . ≥ βˆip. (2)
Determining all the DAGs that are present in the Markov equivalence class can be highly computationally
intensive in a high-dimensional setting. Nevertheless, rather than computing all the DAGs, it is still possible to
determine the set of parents used for adjusting by extracting them from the CPDAG. The local algorithm used
by Maathuis et al. [1] checks if the parents are locally valid (if they create or not a new collider) in the CPDAG
and all causal estimates for a single covariate Xi on Y are in the multiset θi = {θij} with j ∈ {1, . . . ,m} and
i ∈ {1 . . . , p}. Contrary to a set, in a multiset the replication of an element matters. For instance, the multisets
{a, a, b} and {a, b} are not equal while the sets {a, a, b} and {a, b} are. The multiset allows the multiplicity of
an element. Finally, the assumptions made in the IDA are:
1. There are no hidden variables.
2. The joint distribution of covariates Xi, . . . , Xp is normal and faithful to the true (unknown) DAG.
3. CovariatesXi, . . . , Xp have equal variance.
The IDA method developed by Maathuis et al is implemented in the R-package pcalg [16].
2.2.2 PC-algorithm
The PC-algorithm is a constraint based method for causal structure learning [2, 17], meaning that it learns the
causal structure based on the conditional dependencies between variables. A sketch of the PC-algorithm is
given in algorithm 1.
First, it estimates the skeleton of the underlying structure by checking all given conditional dependencies
between each variable at a significance level α. If no information on dependencies is given, then the graph
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Algorithm 1: PC-algorithm
Input: Data D = {X1, ..., Xp}, set of ordered vertex V, significance parameter α
1 Determine the skeleton;
2 Determine the v-structures;
3 Orient as many of the remaining edges as possible;
Output: CPDAG Gˆ
used as input is an undirected graph such as in Figure 1. Once the skeleton is obtained, edges are oriented in
the v-structures to meet the conditional dependencies and finally the CPDAG is obtained by directing as many
remaining edges as possible according to three rules [18]:
1. When there is a triple Xi → Xj −Xk and Xi, Xk not adjacent, orient Xj −Xk as Xj → Xk
2. When there is a triple Xi → Xk → Xj , orient Xi −Xj as Xi → Xj
3. When there are two triples Xi −Xl → Xj and Xi −Xk → Xj with Xk and Xl not adjacent, Xi −Xj
is oriented into Xi → Xj .
Even though the PC-algorithm has been shown to be consistent in high-dimensional settings [19], one of its
issues remains the effect of the set of ordered variables O in the final output. In fact, the order of the variables
determines which pair of nodes is tested first, determining which edges are removed first and so affecting which
tests are considered later on. This order dependence impacts robustness of the results in high-dimensional
settings. Two different solutions have been suggested: the stability ranking and the PC-stable, which will be
outlined below. Before running the algorithm, the multiple testing requires to specify the significance level (cut-
off) α for the conditional independence tests. In fact, setting α to a certain value means that only conditional
dependencies with a p-value under α are kept. Thus, running PC-algorithm with a small value of alpha leads
to obtain sparser graphs.
2.2.3 Stability selection
To deal with the order dependence issue of the PC-algorithm in the IDA which can lead to poor robustness,
Stekhoven et al. proposed to add a stability selection step [20] to IDA. This method, called Causal Stability
ranking (Cstar) [21], is based on a re-sampling approach. The IDA is run over 100 independent random
subsamples and then in each subsampling run, the variables are ranked according to (2). At the end of all
runs, the relative frequencies pii of covariates appearing among the top of q variables are used to define a stable
ranking:
Πˆi1 ≥ Πˆi2 ≥ . . . ≥ Πˆip. (3)
For a given q, a bound for the per-comparison error rate (PCER) which can be seen as the false positive
error rate is given by:
1
2Πˆj − 1
q2
p2
(4)
2.2.4 PC-stable
Another approach that considers the order dependence issue of the PC-algorithm was explored by Colombo and
Maathuis by introducing an order independent version of the PC-algorithm called PC-stable [22]. In step 1 of
the PC-stable version, the adjacency set of all variables are stored after each change in the size of the separation
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set (see section 4.1 of [22]); removing an edge will not affect which conditional independencies are checked
for other pairs of variables. In addition, they also showed that the combination of the stability selection with
PC-stable in gave more reliable edges than PC-stable alone on yeast gene expression data [22].
2.3 Extension to a time-dependant exposure
We aimed to extend the IDA by integrating time-dependent exposures in the PC-stable step. Based on
chronologically ordered data, the resulting CPDAG should not contain arrow from a descendant to a parent
X1,t′ → X1,t where t < t′ since the value of a variable at time t′ cannot influence a past value of the same
variable. This means also that in the first step, when looking at conditional dependencies between two variables
measured at time t and t∗ where t ≥ t∗, variables measured at a time t′ where t′ > t and t′ > t∗ should not be
tested for the separation set S.
Figure 2: Initial graphs used as input for the IDA with and without chronological a priori information for 2 variables
Xi, Xj measured at 3 time points t1, t2 and t3.
This can be done by adding chronological order information among the variables in addition to the condi-
tional independence information as input of the PC-stable algorithm. The result of combining these two types
of information can be viewed as a partially directed graph. In the partially directed graph, all edges between
variables measured at different times should be directed chronologically, from parents to descendants, and
edges between variables measured at the same time remained undirected. Differences between the two initial
graphs with 2 variables measured at 3 time points are shown in Figure 2. A global sketch of the chronologically
ordered PC-stable is shown in algorithm 2.
Algorithm 2: Chronologically ordered PC-algorithm
Input: Data D = {X1, ..., Xp}, set of ordered vertex V, significance parameter α, chronological
information
1 Determine the skeleton (using chronological information);
2 Orient edges according to the chronological information;
3 Determine the v-structures;
4 Orient as many of the remaining edges as possible;
Output: CPDAG Gˆ
The modified step 1 leads thus to determine a skeleton at the end of step 1 while testing only conditional in-
dependences within a same time slice. Then before determining the v-structures, the chronological information
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is used in step 2 to orientXi,t−Xi,t+1 intoXi,t → Xi,t+1. We will call this extension of PC-algorithm chrono-
logically ordered PC-stable (COPC-stable) when using the order dependent version or the COPC- algorithm
when not.
2.3.1 Estimation of the causal effect of repeated continuous covariates on a binary outcome
The estimation of causal effects for data with only continuous or only discrete data has been largely discussed
[3, 23]. In estimate causal effect of repeated continuous covariates on a binary outcome, the collinearity may
address an issue of unstable maximum likelihood estimates. Therefore we used the Firth’s correction to address
this problem [24, 25]. Our model is detailed in the appendix A.
2.3.2 Simulations
To compare our algorithm COPC to the PC-stable algorithm, we used simulations. We generated random
weighted DAGs with a given number of variables p per visit, a given number of visits nvisits(corresponding
to measurements of these variables) and a single binary outcome. To simulate collinearity between repeated
measures, we generated the repeated covariates data from a multivariate distribution that uses an autoregressive
model for the correlation between biomarkers:
X ∼ N
(
µ =

µ1
...
µp
 ,Σ =

ρ0σ2 . . . ρnvisitsσ2
...
. . .
...
ρnvisitsσ2 . . . ρ0σ2

)
, (5)
where ρ is the correlation between biomarkers. We choose to set µ = 0, σ2 = 1 and vary ρ from 0.5 to
0.7. We also tried different number of visits and observations from 3 to 6 and 50 to 1000 respectively. To
evaluate the two methods, we compared the capacity of recovering the true CPDAG through the sensibility and
the specificity which determine the capacity of detecting the true presence of an arrow and the true absence of
an arrow respectively. We also calculated the Structural Hamming distance (SHD) described by Tsamardinos
[26] which is a score to evaluate the structural distance from an estimated graph to a true graph. The SHD
was calculated as follows: SHD was incremented when there was a wrong connection (i.e. there was an arrow
in the estimated CPDAG that was absent in the true CPDAG), and a missed edge (i.e. there was no arrow in
the estimated CPDAG that was present in the true CPDAG). The accuracy of the causal effects estimation was
explored by calculating the mean squared errors (MSE). The full details of the simulations set-up are available
in appendix B.
2.4 Application
The method described above was applied on observational data of repeated immunological biomarkers from pa-
tients treated with ipilimumab for metastatic melanoma. The objective was to highlight immunologic biomark-
ers that had a causal effect on early toxicity, premature death and progression.
2.4.1 Patients
Patients with metastatic melanoma treated with ipilimumab were prospectively enrolled at the Gustave Roussy
Cancer Campus. Ipilimumab was administered intravenously every 3 weeks. Immunological biomarkers were
measured at each visit prior each ipilimumab infusion (V1, V2, V3, andV4).
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2.4.2 Outcomes
Three binary outcomes such as toxicity, premature death and progression were investigated. Early toxicity was
defined as occurrence of colitis 12 weeks after treatment initiation. Premature death referred at death 12 weeks
after treatment initiation. Progression was defined as an increase of at least 20% in tumor size or occurrence of
new lesions 6 months after treatment initiation.
2.4.3 Imunological biomarkers
Several biological models were used representing different level of immunological expression (Table 1). Model
1 represents adaptive T cells in a global way while model 3 represents subgroup of adaptive T cells. In all three
models biomarkers with a potentially known effect were incorporated. For convenience, all biomarkers have
been anonymised in the main text of this page but are fully detailed in appendix C.
Table 1: Biological models representing different level of immunological expression
Model Common biomarkers (n) Adaptative T cells (n)
Number total
of covariates
1
Non-immunologic and innate
immunological biomarkers (29) CD4 and CD8 (8) 37
2
Non-immunologic and innate
immunological biomarkers (29)
CD4/CD8 expressing polarization
and domiciliation markers(148) 177
3
Non-immunologic and innate
immunological biomarkers (29)
Subgroup of CD4 and CD8
expressing polarization
and domiciliation markers (232)
261
2.4.4 Representation
To identify the dependency structure of the data, CPDAGs were estimated using the PC-algorithm. To resume
the (conditional) dependencies present in all CPDAGs, Kalisch et al [14] proposed to aggregate edges in a
present in CPDAGs from a resampled dataset rather than showing a single estimate of the CPDAG. Only edges
present in 20% of the CPDAGs are drawn and their thickness is proportional to the number of CPDAGs in
which the edge was present.
2.4.5 Missing data
In our melanoma application, around 15% of missing data were imputed using multivariate imputation by
chained equations (MICE) [27]. Missingness graphs [28] are substantives tools that have been developed to
study the missingness mechanisms and the recoverability of a missing variable. We applied missingness graphs
on our data in order in to identify the missingness mechanisms and the recoverability. In missing at random
(MAR) case, the missing values can be recovered without bias; while in the missing not at random (MNAR)
case, the missing values could be recovered with some little bias. Full details are provided in the appendix D.
3 Results
3.1 Simulations
The results of the simulations are presented in table 2.
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Table 2: Average sensibility, specificity and SHD according PC-stable and COPC-stable over 500 replicates simulated
based on 2 DAGs with different number of visits.
nvisits nobs alpha
Se PC-stable
(sd) %
Se COPC-
stable (sd) %
Sp PC-stable
(sd) %
Sp COPC-
stable (sd) %
SHD PC-
stable (sd)
SHD COPC-
stable (sd)
4
1000 0.02 58.1(0.6) 63.2(0.5) 98.7(0.1) 98.8(0.1) 333 (9) 279 (7)0.2 58.1(0.5) 64.1(0.5) 98.6(0.1) 98.5(0.1) 340 (9) 288 (8)
50 0.02 54.9(0.5) 57.0(0.6) 99.2(0.1) 99.4(0.1) 338 (8) 299 (9)0.2 56.3(0.6) 59.0(0.6) 98.9(0.1) 99.1(0.1) 339 (9) 296 (8)
6
1000 0.02 56.6(0.4) 60.7(0.4) 99.0(0.1) 98.9(0.1) 504 (10) 466 (8)0.2 56.6(0.4) 61.6(0.4) 98.9(0.1) 98.6(0.1) 521 (9) 491 (10)
50 0.02 54.1(0.3) 55.6(0.4) 99.4(0.1) 99.5(0.1) 484 (9) 455 (11)0.2 55.2(0.4) 57.5(0.5) 99.2(0.1) 99.3(0.1) 494 (11) 454 (12)
Overall, COPC-stable outperformed PC-stable in terms of sensibility, meaning that the percentage of false
positive was lower in the CPDAGs estimated with COPC-stable rather than the CPDAGs estimated with PC-
stable. In terms of specificity, both algorithms showed excellent results. In scenarios with a greater alpha level
regarding other parameters, sensibility rose while specificity decreased. Reducing the number of observations
from 1000 to 50 made the sensitivity and specificity slightly underestimated.
The COPC-stable SHD was lower than the PC-stable in all scenarios, meaning that, as compared with CPDAGs
estimated with PC-stable, CPDAGs estimated with COPC-stable had a structure closer to the true CPDAG (see
table 2).
In terms of accuracy, the estimations of causal effects based on CPDAGs estimated with COPC-stable were
more accurate than the ones using CPDAGs estimated with PC-stable (see appendix E for results of all scenar-
ios).
3.2 Application
Both IDA and our extension have been applied on our observational data of repeated immunological biomark-
ers from patients treated with immunotherapy for metastatic melanoma. They have been repeatedly run 300
times on subsamples of size n=30. The tuning parameter α was set to 0.02.
As expected, CPDAGs obtained using a naı¨ve PC-stable from unordered repeated measures led to non-
chronological ordered paths in all three models (Figure 3) as compared with paths identified through COPC.
Table 3: Average number of edges (standard deviation) in the CPDAG according to the version of the PC-algorithm and
the model over 300 runs with α = 0.02.
Directed edges (sd) Bidirected edges (sd) Non-chronologicallyordered edges (sd) Total (sd)
PC-algo (model 1) 0 (0.1) 23 (0.2) 17 (0.2) 22 (0.1)
COPC-algo (model 1) 27 (0.2) 7 (0.3) 0 (0) 34 (0.3)
PC-algo(model 2) 3 (0.2) 120 (0.5) 76 (0.5) 122 (0.5)
COPC-algo (model 2) 120 (0.6) 58 (0.4) 0 (0) 178 (0.6)
PC-algo (model 3) 5 (0.2) 197 (0.8) 101 (0.7) 202 (0.7)
COPC-algo (model 3) 153 (1) 112 (0.7) 0 (0) 265 (1)
Table 3 shows the average number of edges according to the version of the PC-algorithm and the model.
As compared with PC-stable, the percentage of bidirected edges among all edges using COPC-stable was on
average smaller in all three models, 100% vs 28% for model 1, 98% vs 40% for model 2 and 97% vs 52% for
model 3. Moreover, Table 3 shows how many edges are defined wrongly into the final CPDAG. For instance,
in model 1, when using a naı¨ve approach of the PC-stable, the resulting CPDAG had on average 14 bidirected
edges that were between two variables measured at different times. When looking at Table 4, the number of
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Figure 3: Subset of the summary CPDAGs (Completed partially DAGs) of the model 3 in the metastatic melanoma example
using naive PC-stable over 300 runs. Only edges with a frequency> 0.20 are present. The thickness of edges is proportional
to their frequency.
values in each multiset θi also called ambiguity (aˆ) of the multiset [1] was smaller when using COPC-stable
rather than PC-stable for a same value of alpha (α = 0.02). The maximum ambiguity reached in our application
was 3.
Table 4: Probability of having a certain ambiguity aˆ for biomarkers with an alpha level at 0.02 according to the version of
the PC-algorithm (PC-Stable/ COPC-stable) over 300 with α = 0.02
Ambiguity
Model 1 Model 2 Model 3
PC-stable COPC-stable PC-stable COPC-stable PC-stable COPC-stable
aˆ = 1 0.243 0.676 0.153 0.599 0.061 0.437
aˆ = 2 0.568 0.297 0.655 0.356 0.693 0.494
aˆ = 3 0.189 0.027 0.192 0.045 0.245 0.069
3.2.1 Estimating time-dependent causal effects in the melanoma example
After estimating the CPDAG using COPC-stable, causal effects were estimated using Pearl’s do-calculus. To
determine which biomarker had a robust causal effect, we intended to select biomarkers with PCER threshold
≤ 0.5%. In model 1, there were no biomarkers with a PCER ¡ 0.005. Figures 4 and 5 show histograms of causal
effects on our three outcomes death, progression and toxicity based on model 2 and 3. The causal effects seem
almost uniformly distributed between 0 and 1 in our example for models 2 and 3. However, immunological
biomarkers with a PCER under 0.5% had a causal effect concentrated between 0.6 and 0.8 for models 2 and 3
for all outcomes. On the other hand, causal effects sizes of immunological biomarker with PCER > 0.5% were
spread in a wide range from 0 to 1.
Tables 5 shows the top effect biomarkers among those selected for models 2 (see appendix F for the list of all
selected immunological biomarkers).
We see that some of the biomarkers are present in all top 10 but differ with the time of measurement. We
see that BM30 is present in the top 10 of toxicity at visit 1, in the top 10 of progression at visit 3 and in the top
ten of the death at visit 4. Other biomarkers are present in 2 of the top 3 but differ with the visit such as BM26,
BM45, BM39 and BM9.
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Figure 4: Histogram of the causal effect for the biomarkers on death, progression and toxicity based on model 2 over
300 runs. Solid and dashed lines represent the kernel density of biomarkers with a PCER > 0.5% and PCER ≤ 0.5%
respectively.
Table 5: Top 10 of immunological biomarkers with a PCER < 0.5% in model 2. The number following “v” stands for the
visit number. Superscript indicate biomarkers in common. See appendix C for the complete description of the biomarkers.
Rank Death (12 weeks) Progression (6 months) Toxicity 12 weeks
Biomarker
Median
effect PCER Biomarker
Median
effect PCER Biomarker
Median
effect PCER
1 BM16v2a 0.81 0.0035 BM8v1d 0.77 0.0031 BM7v4 0.79 0.0028
2 BM5v1 0.81 0.0035 BM44v4 0.72 0.0036 BM8v4d 0.76 0.0034
3 BM42v3 0.8 0.0037 BM26v2 0.71 0.0041 BM16v3a 0.75 0.0036
4 BM48v1 0.86 0.0037 BM30v3b 0.71 0.0041 BM26v4 0.75 0.0036
5 BM42v2 0.8 0.0038 BM44v3 0.68 0.0042 BM7v3 0.76 0.0037
6 BM14v4 0.79 0.0039 BM45v1e 0.7 0.0047 BM9v4c 0.72 0.0039
7 BM30v4b 0.8 0.0039 BM39v4f 0.66 0.0049 BM39v3f 0.72 0.0039
8 BM11v4 0.83 0.004 BM40v4 0.66 0.0049 BM32v3 0.71 0.0042
9 BM11v1 0.76 0.0042 BM14v2 0.66 0.005 BM30v1b 0.67 0.0045
10 BM9v4c 0.81 0.0043 - - - BM45v1e 0.71 0.0046
4 Discussion
We extended in this paper the IDA method to repeated measures by introducing a chronologically ordered (CO)
version of the so called PC-algorithm. Our proposed algorithm COPC-algorithm takes a priori chronological
information such as repeated measure into account in the input graph. We applied then PC-stable and our new
method COPC-stable to simulated data sets and observational data of repeated immunological biomarkers from
patients treated repeatedly with immunotherapy for metastatic melanoma. When comparing CPDAGs obtained
with PC-stable and those with COPC-stable, the simulation study showed that PC-stable had a lower sensitivity
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Figure 5: Histogram of the causal effect for the biomarkers on death, progression and toxicity based on model 3 over
300 runs. Solid and dashed lines represent the kernel density of biomarkers with a PCER > 0.5% and PCER ≤ 0.5%
respectively.
than the COPC-stable leading to a better learning of the true structure. On the application, CPDAGs based on
PC-stable had indeed non-chronological ordered paths while those based on COPC-stable could not have any.
CPDAGs obtained with COPC-stable had on average more total and directed edges than those obtained with
PC-stable but less bidirected edges. The lower the number of directed edges, the lower the number of possible
ways to direct edges, and hence the lower the number of DAGs in the Markov equivalence class. Moreover
Table 4 showed that when using COPC-stable, the proportion of values obtained in the multiset θi was on av-
erage lower when using PC-stable. Smaller is the Markov equivalence class, higher is the power of the study
to identify causal effects.
In the COPC-stable, the number of tested conditional dependencies is considerably smaller than with PC-stable.
Since it takes chronological order information into account, the COPC-algorithm does not test dependencies of
two variables conditioning on a variable measured at a time after those two variables. In contrary, the original
PC-algorithm tests non-realistic conditional dependences and thus raises the number of global tests. Testing
those non-realistic conditional dependences could lead to identify false positive causal effects.
Finding the true causal DAG has always been the principle interest of causal inference studies, knowing the
true causal DAG allows estimating the true causal effect. However, in high-dimensional setting, the true causal
DAG is generally unknown and it is difficult to check whether or not all possible confounders are measured. In
this case, causal effects cannot be uniquely estimated. Therefore IDA was developed to estimate lower bounds
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of the causal effects of Xi on Y and determine the importance of these effects. This is a different approach
where instead of searching one true causal effect, a range of causal effects are estimated in each DAG from a
Markov equivalence class. Consequently, when effect of large numbers of markers is identified, those which
have causal effects could be selected by different approaches. In fact, we could either keep a small range of
biomarkers that are in the top effects as in [21] or a larger range of those with a limited but slightly higher prob-
ability of being false positive. In the high-dimensional setting, the first approach will keep biomarkers with
the strongest causal effect but not necessarily all biomarkers with a small causal effect. The second approach
assures to select a larger list of biomarkers that have a robust causal effect and will suggest to clinicians which
immunological biomarkers they should investigate deeper in a follow-up study. Also, controlling for type 1
error can be done by different methods. We choose in our application the PCER because it is less restrictive
compared to methods such as FDR (False discovery rate) or FWER (Family-wise error rate).
The choice of the selecting approach depends on the objective: selecting a small list of biomarker that have the
highest effect on the outcome or identifying all the biomarkers that have an effect regardless of the size effect.
For instance, if only the measure of a marker at visit 2 belongs to the top causal effects, is only the measure at
visit 2 is important or should the marker be measured at all visits ?
Usually, in a causal DAG, all true causal effects have to be reported, not only the strongest. Nevertheless, the
interpretation of the top causal biomarker is challenging. Having a biomarker at a certain visit with a PCER
below the selected threshold does not mean that the biomarker has a causal effect only at this visit but rather
its maximum and more robust effect at this visit. One of the main assumptions made in this study is that the
true DAG is not dynamic like other extensions of the PC-algorithm on time-series data [29, 30]. So we did
not constrain the arrows to be the same within each visit. In fact, the context of biological biomarkers can be
much more complex than a simple repetition of a pattern. Originally, the IDA made the assumption that all
variables including the outcome were Gaussian, then it has been extended in a case where all variables (includ-
ing outcome) are discrete [14]. In this study we made the assumption that all covariates X = {X1, . . . , Xp}
are Gaussian and that the outcome is binary because it is a situation that is quite common in oncology. Also,
the covariates need to be measured at uniform set of time points (i.e. balanced data).
Our work was motivated by finding causal effects among repeated immunological biomarkers on death and
toxicity of patients treated with immunotherapy for metastatic melanoma. Based on our observational data,
using the IDA with our new version of the PC-algorithm, the COPC-algorithm, we found a consistent list of
immunological biomarkers with causal effects. But one should be attentive not to overinterpret these results. It
is in fact impossible in an accurate way to check whether or not our assumptions hold; having no unmeasured
confounders is a strong assumption but may be reasonable in our application.
Further work will investigate the adding of expert knowledge as input of the COPC-algorithm based on high-
dimensional graphs. Also we will explore extensions that can deal with longitudinal and time to event out-
comes.
5 Conclusion
We presented in this paper, an extension of the PC-algorithm called COPC-algorithm. It provides CPDAGs that
keep the chronological structure present in the data and allow us thus to estimate reliable lower bounds of the
causal effect of repeated covariates or biomarkers. In the immunotherapy example, immunological biomarkers
on early toxicity, premature death and progression were identified and will be further investigated by clinicians.
13
6 Declarations
Ethics approval and consent to participate
Patients were informed of the study and consented to participate. This study was approved by the Kremlin
Biceˆtre Hospital Ethics Committee (SC12-018; ID-RCB-2012-A01496-37) and all procedures were performed
in accordance with the Declaration of Helsinki.
Competing interest
The authors declare that they have no competing interests.
Funding
This work is part of a PhD thesis funded by Universite´ Paris Sud.
This study was funded by Gustave Roussy Cancer Campus, Fondation Gustave Roussy, the Institut national de
la sante´ et de la recherche me´dicale (INSERM), the Direction Ge´ne´rale de l’Offre de Soins (DGOS; GOLD
TRANSLA 12-174), the Institut National du Cancer (INCa; GOLD 2012-062 N Cance´ropoˆle : 2012-1-RT-14-
IGR-01), and SIRIC SOCRATE (INCa DGOS INSERM 6043), MMO program: ANR-10IBHU-0001).
Authors’ contributions
VA, SM, EM have conceived the statistical work, VA has drafted the manuscript. CC and NC provided im-
munological data and helped for the immunological interpretation. CR provided clinical data and help for
clinical interpretation. All authors have critically reviewed the manuscript.
Acknowledgements
Vahe´ Asvatourian was supported by Universite´ Paris Sud. Clelia Coutzac was supported by fellowships from
Fondation pour la Recherche Me´dicale (FRM).The authors would like to thank Gustave Roussy Cancer Cam-
pus, INSERM and INCa for their funding.
References
[1] Marloes H. Maathuis, Markus Kalisch, and Peter Bu¨hlmann. Estimating high-dimensional intervention
effects from observational data. Annals of Statistics, 37(6 A):3133–3164, 2009.
[2] Peter. Spirtes, Clark Glymour, and Richard. Scheines. Causation, Prediction, and Search. Springer Verlag,
1993.
[3] Judea Pearl. Causality: Models, Reasoning, and Inference. Cambridge University Press, 2nd edition,
2009.
[4] M A Hernan, B Brumback, and J M Robins. Marginal structural models to estimate the causal effect of
zidovudine on the survival of HIV-positive men. Epidemiology, 11(5):561–570, 2000.
[5] James M. Robins, Miguel A´ngel Herna´n, and Babette Brumback. Marginal structural models and causal
inference in epidemiology. Epidemiology, 11(5):550–560, 2000.
14
[6] Caroline Robert, Luc Thomas, Igor Bondarenko, Steven O’Day, Jeffrey Weber, Claus Garbe, Celeste
Lebbe, Jean-Franc¸ois Baurain, Alessandro Testori, Jean-Jacques Grob, Neville Davidson, Jon Richards,
Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascon, Michal Lotem, Kaan Harmankaya, Ramy
Ibrahim, Stephen Francis, Tai-Tsang Chen, Rachel Humphrey, Axel Hoos, and Jedd D. Wolchok. Ip-
ilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of
Medicine, 364(26):2517–2526, 2011.
[7] F. Stephen Hodi, Steven J. O’Day, David F. McDermott, Robert W. Weber, Jeffrey A. Sosman, John B.
Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C. Hassel, Wallace Akerley, Al-
fons J.M. van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M. Vaubel, Gerald P. Linette, David Hogg,
Christian H. Ottensmeier, Celeste Lebbe´, Christian Peschel, Ian Quirt, Joseph I. Clark, Jedd D. Wolchok,
Jeffrey S. Weber, Jason Tian, Michael J. Yellin, Geoffrey M. Nichol, Axel Hoos, and Walter J. Urba.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of
Medicine, 363(8):711–723, 2010.
[8] Charles G. Drake, Evan J. Lipson, and Julie R. Brahmer. Breathing new life into immunotherapy: Review
of melanoma, lung and kidney cancer. Nature Reviews Clinical Oncology, 11(1):24–37, 2014.
[9] Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid,
Debra Patt, Tai Tsang Chen, David M. Berman, and Jedd D. Wolchok. Pooled analysis of long-term
survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma.
Journal of Clinical Oncology, 33(17):1889–1894, 2015.
[10] C. Garbe, T. K. Eigentler, U. Keilholz, A. Hauschild, and J. M. Kirkwood. Systematic Review of Medical
Treatment in Melanoma: Current Status and Future Prospects. The Oncologist, 16(1):5–24, 2011.
[11] Daniel J. Sargent, Barbara A. Conley, Carmen Allegra, and Laurence Collette. Clinical trial designs for
predictive marker validation in cancer treatment trials. Journal of Clinical Oncology, 23(9):2020–2027,
2005.
[12] Marc Buyse, Stefan Michiels, Daniel J. Sargent, Axel Grothey, Alastair Matheson, and Aimery De Gra-
mont. Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 11(2):171–182,
2011.
[13] Judea Pearl. Causal diagrams for empirical research. Biometrika, 82(4):669–688, 1995.
[14] Markus Kalisch, Bernd Ag Fellinghauer, Eva Grill, Marloes H. Maathuis, Ulrich Mansmann, Peter
Bu¨hlmann, and Gerold Stucki. Understanding human functioning using graphical models. BMC Medical
Research Methodology, 10(1):10–14, 2010.
[15] Judea Pearl. Statistics and causal inference: A review. Test, 12(2):281–345, 2003.
[16] Markus Kalisch, Martin Machler, Diego Colombo, Marloes H Maathuis, Peter Buhlmann, M Ma¨chler,
Diego Colombo, and Marloes H Maathuis. Causal Inference Using Graphical Models with the R Package
pcalg. Journal of Statistical Software, 47(11):26, 2012.
[17] Marloes H. Maathuis and Preetam Nandy. A review of some recent advances in causal inference. In
handbook of big data. Chapman and Hall, 2016.
[18] Christopher Meek. Causal inference and causal explanation with background knowledge. Proceeding
UAI’95 Proceedings of the Eleventh conference on Uncertainty in artificial intelligence, pages 403–410,
1995.
15
[19] Markus Kalisch and Peter Buehlmann. Estimating high-dimensional directed acyclic graphs with the
PC-algorithm. Journal of Machine Learning Research, 8:613–636, 2007.
[20] Nicolai Meinshausen and Peter Bu¨hlmann. Stability selection. Journal of the Royal Statistical Society.
Series B: Statistical Methodology, 72(4):417–473, 2010.
[21] Daniel J. Stekhoven, Izabel Moraes, Gardar Sveinbjo¨rnsson, Lars Hennig, Marloes H. Maathuis, and
Peter Bu¨hlmann. Causal stability ranking. Bioinformatics, 28(21):2819–2823, 2012.
[22] Diego Colombo and Marloes H. Maathuis. Order-independent constraint-based causal structure learning.
Journal of Machine Learning Research, 2012.
[23] Miguel A. Herna´n and James M. Robins. Causal Inference. Chapman and Hall/CRC, 2018.
[24] David Firth. Bias reduction of maximum likelihood estimates. Biometrika, 80(1):27–38, 1993.
[25] Georg Heinze and Michael Schemper. A solution to the problem of separation in logistic regression.
Statistics in Medicine, 21(16):2409–2419, 2002.
[26] Ioannis Tsamardinos, Laura E. Brown, and Constantin F. Aliferis. The max-min hill-climbing Bayesian
network structure learning algorithm. Machine Learning, 65(1):31–78, 2006.
[27] St van Buuren, Groothuis-Oudshoorn, and K. MICE: Multivariate Imputation by Chained Equations in
R. Journal of Statistical Software, 45(3), 2012.
[28] Karthika Mohan, Judea Pearl, and Jin Tian. Graphical Models for Inference with Missing Data. Advances
in Neural Information Processing System 26, (December):1–9, 2013.
[29] Tianjiao Chu and Clark Glymour. Search for Additive Nonlinear Time Series Causal Models. Journal of
Machine Learning Research, 9:967–991, 2008.
[30] Kay H. Brodersen, Fabian Gallusser, Jim Koehler, Nicolas Remy, and Steven L. Scott. Inferring causal
impact using bayesian structural time-series models. Annals of Applied Statistics, 9(1):247–274, 2015.
16
Appendix A Estimation of the causal effect of a repeated biomarker 
on a binary outcome 
Causal effects of    on the outcome   can be quantified by measuring the difference of any 
function of the distribution of “counterfactuals outcome” such as mean, median or ratios (see 
technical point 1.1 of  [1]). Let G be a directed acyclic graph with V the set of nodes 
described by        variables          . 
Pearl [2] showed that the distribution generated from a DAG is called Markovian and can be 
factorized as 
( )                                     (              )  ∏ (  |  (  )) 
   
   
 
Intervention on a variable using Pearl’s do operator assigns a value to the variable over the 
population; and the distribution generated on the variables set can be expressed in the 
truncated factorization formula:  
( )                         (                 (      )  
{
 
 
∏  (  |  (  ))            
   
       
                                            
 
  
 
 
Equation (2) reflects the removal in (3) of  (  |  (  )) since   (  ) has no effect on   . 
Graphically, removing  (  |  (  )) is equivalent to removing the arrows from    (  ) to   .   
Based on (2), Pearl’s has shown that the effect of the intervention   (    
 
 ) on Y is given 
by 
( )                         (    (    
 
 )  ∑  (    (    
 
 )   (  )  (  (  ))
  (  )
  
Equation (3) means conditioning   (    (    
 
 ) on the parents of    and then averaging 
the results weighted by the probability of   (  ). 
For a continuous outcome,  (    (    
 
 )   ( |  (    )), which denotes the mean 
of   when    is uniformly assigned to   over the population. So we can defined the average 
causal effect for a continuous outcome Y  by  
( )                                     ( |  (    ))   ( |  (      ))  
where  (    (     ))  and  ( |  (      )) denote the mean of   when    is uniformly 
assigned to   or     over the population via Pearl’s do operator. In the case of continuous 
Gaussian variables, the causal effect of    on Y is the regression coefficient    of    in the 
linear regression of Y on    and pa(Xi,G) [1, 2]: 
( )                                   ( |     (    ))                     
However, in the case where covariates         are Gaussian and the outcome Y is binary, 
the linearity stated in (5) does not hold. This is why we modelled the relation using a logit link 
that allows keeping the linearity and calculating the causal effect for a binary outcome as 
( )                                      (   |     (    ))                    
This method of modelling is widely used in [1] (see technical point 11.1). 
However, the “separation” phenomenon [3] could occur in small datasets in logistic 
regression such as in our melanoma example: subjects having     and subjects having 
    can be separated by a single or a combination of covariates, the likelihood converges 
while at least one parameter estimate diverges to  , leading to infinite odds ratio estimates. 
To overcome this situation, Firth proposed to reduce the bias of maximum likelihood 
estimates [4]. Several studies have shown that this method provides unbiased estimates [5, 6]. 
In our small observational dataset setting, the causal effects on dichotomous outcome will be 
estimated through logistic regression with Firth correction.   
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Appendix B Simulation set-up
In this additional file, we explain how we run our simulations and what scenarios we tested. In our scenarios, we fixed
the number of variables, of maximum parent per node and the correlation between biomarkers. We tested different
value for the number of observations, the number of measurement (visits) and for the independence test cut-off alpha
leading to a total of 8 scenarios.
Scenarios
We generated data faithful to a by using the following parametrisations:
• p = 20
• nvisits ∈ {4, 6}
• maxP = 3
• n ∈ {50, 1000}
• α ∈ {0.02, 0.2}
• ρmin = 0.5, ρmax = 0.7
• σ = 1
For each scenario we generated a DAG with p ∗ nvis + Y variables and then sampled 500 different datasets per
DAG. We calculated the average SHD, sensibility and specificity for estimated CPDAGs with both CP-stable and
COPC-stable based on the 500 datasets.
Generate a DAG with repeated measures of covariates
To generate a DAG that has repeated measures and an expected number of parents per node maxP , we used the
following approach: first, we generated a (p× nvisits + Y )× (p× nvisits + Y ) weighted matrix wM , where p is the
number of biomarkers, nvisits the number of visits (measurements) and Y the outcome; with independent realizations
of Uniform(0.5, 1) in the upper triangle of the matrix and zeroes in the remaining entries. At the end, if wMi,j > 0
then, it meant there was an arrow from Xi to Xj (Xi → Xj) with a weight of wMi,j . The maximum parent for each
node was limited by maxP . Then, based on the true DAG obtained, we generated i.i.d samples using algorithm 1.
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Algorithm 1: Generation of data based on a DAG with repeated measures of covariates with a single
outcome
Input: number of observations (n), weighted matrix (wM ), sigma (σ), ρmin, ρmax, number of biomarkers
(p), number of measurements (nvisits)
for Subject i← 1 to n do
for Number of Biomarkers j ← 1 to p do
Let Vj be the set of measurements for the biomarker j
Let the vector µVj = E(V1) = E(V2) = E(Vnvisits) = 0
ρj ∼ Uniform(ρmin, ρmax)
Σj =

σ2 ρ1σ2 ρ2σ2 . . . ρnvisitsσ2
ρ1σ2 σ2 ρ1σ2 . . . ρnvisits−1σ2
ρ2σ2 ρ1σ2 σ2 . . . ρnvisits−2σ2
...
...
... . . .
...
ρnvisitsσ2 ρnvisits−1σ2 ρnvisits−2σ2 . . . σ2

i,Vj ∼ Nnvisits(µj,Σj)
i,Outcome ∼ N(0, 1)
end
end
ptot = p× nvisits + 1 (outcome)
for Subject i← 1 to n do
for Variable v ← 1 to ptot do
if V ariablev has no parent then
V ariablei,v = V ariablei,v
end
else if V ariablev has at least 1 parent then
V ariablei,v =
∑nparents
j=1 (wMj,v × PAj(V ariablei,v)) + V ariablei,v
if v = p then
V ariablei,p ∼ Bernoulli(logit−1(V ariablei,ptot))
end
end
end
end
Output: Simulated database
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Appendix C Description of all anonymised biomarkers of the application  
 
Table 1: Description of the anonymised biomarkers for model 1. The number following “v” stands for the 
visit number. 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Description of the anonymised biomarkers for model 3. The number following “v” stands for the 
visit number.  
Labels Description 
BM 1v1  Interleukin 6 
BM 2 v1 Interleukin 8 
BM 3 v1 Monocyte chemo attractant protein 1 
BM 4 v1 Interferon gamma-induced protein 10 
BM 5 v1 Tumour Necrosis Factor  
BM 6 v1-v4 C reactive protein 
BM 7 v1-v4 Lactate Dehydrogenase 
BM 8 v1-v4 Eosinophils 
BM 9 v1-v4 Neutrophils 
BM 10 v1-v4 Soluble CD25 
BM 11 v1-v4 Soluble CTLA-4 
BM 12 v1-v4 
BM 13 v1-v4 
CD4
+
 T cells 
CD8
+
 T cells 
Labels Description 
BM 1v1  Interleukin 6 
BM 2 v1 Interleukin 8 
BM 3 v1 Monocyte chemo attractant protein 1 
BM 4 v1 Interferon gamma-induced protein 10 
BM 5 v1 Tumour Necrosis Factor  
BM 6 v1-v4 C reactive protein 
BM 7 v1-v4 Lactate Dehydrogenase 
BM 8 v1-v4 Eosinophils 
BM 9 v1-v4 Neutrophils 
BM 10 v1-v4 Soluble CD25 
BM 11 v1-v4 Soluble CTLA-4 
BM 14  v1-v4 % of Foxp3
+
CD25
+
 among CD4
+
 T cells 
BM 15  v1-v4 % of conventional CD4
+
 T cells (Tconv) (FoxP3
-
) 
BM 16  v1-v4 % of CD49d
+7+ among CD4+ T cells 
BM 17  v1-v4 % of CD49d
+7+  among CD4+ T cells 
BM 18  v1-v4 % of 7+CD103+ among CD4+ T cells 
BM 19  v1-v4 % of C-C chemokine receptor 6
+
(CCR6
+
) among CD4
+
 T cells 
BM 20  v1-v4 % of Cutaneous Lymphocyte-associated antigen
+
 (CLA
+
) C-C chemokine receptor 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10
+ 
(CCR10
+
)  among CD4
+
 T cells 
BM 21  v1-v4 % of CLA
+
 among CD4
+
 T cells 
BM 22  v1-v4 % of central memory among CD4
+
 T cells 
BM 23  v1-v4 % of C-X-C chemokine receptor 3
+
(CXCR3
+
) CCR6 
+
 among CD4
+
 T cells 
BM 24  v1-v4 % of CXCR3
+
 chemokine receptor+  among CD4
+
 T cells 
BM 25  v1-v4 % of C-X-C chemokine receptor 5
+
 (CXCR5
+
) chemokine receptor
+
  among CD4
+
 
T cells 
BM 26  v1-v4 % of effector memory among CD4
+
 T cells 
BM 27  v1-v4 % of effector among CD4
+
 T cells 
BM 28  v1-v4 % of memory among CD4
+
 T cells 
BM 29  v1-v4 % of naïve among CD4
+
 T cells 
BM 30  v1-v4 % of CD49d
+
 CD103
+
 among CD8
+
 T cells 
BM 31  v1-v4 % of CD49d
+
 7+ among CD8+ T cells 
BM 32  v1-v4 % of 7+CD103+ among CD8+ T cells 
BM 33  v1-v4 % of CCR10
+
 among CD8
+
 T cells 
BM 34  v1-v4 % of CCR6
+
 among CD8
+
 T cells 
BM 35  v1-v4 % of CLA
+
 CCR10
+
 among CD8
+
 T cells 
BM 36  v1-v4 % of CLA
+
 among CD8
+
 T cells 
BM 37  v1-v4 % of central memory among CD8 T cells 
BM 38  v1-v4 % of CXCR3
+
 CCR6
+
 among CD8
+
 T cells 
BM 39  v1-v4 % of CXCR3
+
 among CD8
+
 T cells 
BM 40  v1-v4 % of CXCR5
+
 among CD8
+
 T cells 
BM 41  v1-v4 % of effector memory among CD8
+
 T cells 
BM 42  v1-v4 % of effector among CD8
+
 T cells 
BM 43  v1-v4 % of memory among CD8
+
 T cells 
BM 44  v1-v4 % of naïve among CD8
+
 T cells 
BM 45  v1-v4 % of Inducible CoStimulator (ICOS
+
) among CD8
+
 T cells 
BM 46  v1-v4 % of Inducible CoStimulator (ICOS
+
) among CD4
+
 T cells 
BM 47  v1-v4 % of Inducible CoStimulator Ligand (ICOSL
+
) among CD4
+
 T cells 
BM 48  v1-v4 %  of High Inducible CoStimulator Ligand (ICOSL
+
) among CD4
+
 T 
cells 
BM 49  v1-v4 % of Inducible CoStimulator Ligand (ICOSL
+
) among CD8
+
 T cells 
BM 50  v1-v4 % of FoxP3
+
 among CD4
+
 T cells 
Table 3: Description of the anonymised biomarkers for model 3. The number following “v” stands for the 
visit number. 
 
Labels Description 
BM 1v1  Interleukin 6 
BM 2 v1 Interleukin 8 
BM 3 v1 Monocyte chemo attractant protein 1 
BM 4 v1 Interferon gamma-induced protein 10 
BM 5 v1 Tumour Necrosis Factor  
BM 6 v1-v4 C reactive protein 
BM 7 v1-v4 Lactate Dehydrogenase 
BM 8 v1-v4 Eosinophils 
BM 9 v1-v4 Neutrophils 
BM 10 v1-v4 Soluble CD25 
BM 11 v1-v4 Soluble CTLA-4 
BM 51  v1-v4 % of CD49d
+
CD103
+
 among central memory CD4
+
 T cells 
BM 52  v1-v4 % of  CD49d
+7+ among central memory CD4+ T cells 
BM 53  v1-v4 % of  7+CD103+ among central memory CD4+ T cells 
BM 54  v1-v4 % of CD49d
+
CD103
+
 among effector memory CD4
+
 T cells 
BM 55  v1-v4 % of CD49d
+7+ among effector memory CD4+ T cells 
BM 56  v1-v4 % of 7+CD103+ among effector memory CD4+ T cells 
BM 57  v1-v4 % of CD49d
+
CD103
+
 among effector CD4
+
 T cells 
BM 58  v1-v4 % of CD49d
+7+ among effector CD4+ T cells 
BM 59  v1-v4 % of 7+CD103+ among effector CD4+ T cells 
BM 60  v1-v4 % of CCR10
+
 among effector CD4
+
 T cells 
BM 61  v1-v4 % of CCR 6
+
 among effector CD4
+
 T cells 
BM 62  v1-v4 % of CLA
+
CCR10 
+
 among effector CD4
+
 T cells 
BM 63  v1-v4 % of CLA
+
 among effector CD4
+
 T cells 
BM 64  v1-v4 % of CXCR3
+
 CCR6
+
 among effector CD4
+
 T cells 
BM 65  v1-v4 % of CXCR3
+
 among effector CD4
+
 T cells 
BM 66  v1-v4 % of CXCR5
+
 among effector CD4
+
 T cells 
BM 67  v1-v4 % of CD49+b7+ among memory CD4
+
 T cells 
BM 68  v1-v4 % of 7+CD103+ among memory CD4+ T cells 
BM 69  v1-v4 % of CCR10
+
 among memory CD4
+
 T cells 
BM 70  v1-v4 % of CCR6
+
 among memory CD4
+
 T cells 
BM 71  v1-v4 % of CLA
+
 CCR10
+ 
among memory CD4
+
 T cells 
BM 72  v1-v4 % of CLA
+
 among memory CD4
+
 T cells 
BM 73  v1-v4 % of CXCR3
+
 CCR6
+ 
among memory CD4
+
 T cells 
BM 74  v1-v4 % of CXCR3
+
 among memory CD4
+
 T cells 
BM 75  v1-v4 % of CXCR5
+
 among memory CD4
+
 T cells 
BM 76  v1-v4 % of CD49d
+
CD103
+
 among naïve CD4
+
 T cells 
BM 77  v1-v4 % of CD49d
+7+ among naïve CD4+ T cells 
BM 78  v1-v4 % of 7+CD103+ among naïve CD4+ T cells 
BM 79  v1-v4 % of CD49d
+
CD103
+
 among central memory CD8
+
 T cells 
BM 80  v1-v4 % of  CD49d
+7+ among central memory CD8+ T cells 
BM 81  v1-v4 % of  7+CD103+ among central memory CD8+ T cells 
BM 82  v1-v4 % of CD49d
+
CD103
+
 among effector memory CD8
+
 T cells 
  
BM 83  v1-v4 % of CD49d
+7+ among effector memory CD8+ T cells 
BM 84  v1-v4 % of 7+CD103+ among effector memory CD8+ T cells 
BM 85  v1-v4 % of CD49d
+
CD103
+
 among effector CD8
+
 T cells 
BM 86  v1-v4 % of CD49d
+7+ among effector CD8+ T cells 
BM 87  v1-v4 % of 7+CD103+ among effector CD8+ T cells 
BM 88  v1-v4 % of CCR10
+
  among effector CD8
+
 T cells 
BM 89  v1-v4 % of CCR6
+
among effector CD8
+
 T cells 
BM 90  v1-v4 % of CLA
+
 CCR10
+
 among effector CD8
+
 T cells 
BM 91  v1-v4 % of CLA
+
 among effector CD8
+
 T cells 
BM 92  v1-v4 % of CXCR3
+
 CCR6
+ 
 among effector CD8
+
 T cells 
BM 93  v1-v4 % of CXCR3
+
 among effector CD8
+
 T cells 
BM 94  v1-v4 % of CXCR5
+
among effector CD8
+
 T cells 
BM 95  v1-v4 % of CCR10
+
 among memory CD8
+
 T cells 
BM 96  v1-v4 % of CCR6
+ 
among memory CD8
+
 T cells 
BM 97  v1-v4 % of CLA
+
 CCR10
+
 among memory CD8
+
 T cells 
BM 98  v1-v4 % of CLA
+
 among memory CD8
+
 T cells 
BM 99  v1-v4 % of CXCR3
+
 CCR6
+ 
 among memory CD8
+
 T cells 
BM 100  v1-v4 % of CXCR3
+
 among memory CD8
+
 T cells 
BM 101  v1-v4 % of CXCR5
+
 among memory CD8
+
 T cells 
BM 102  v1-v4 % of CD49d
+
CD103
+
 among naïve CD8
+
 T cells 
BM 103  v1-v4 % of CD49d
+7+ among naïve CD8+ T cells 
BM 104  v1-v4 % of 7+CD103+  among naïve CD8+ T cells 
BM 105  v1-v4 % of ICOS
+
 cells among Tconv cells 
BM 106  v1-v4 % of ICOSL
+
 cells among Tconv cells 
BM 107  v1-v4 % of ICOSL
+
 cells among Treg cells 
BM 108  v1-v4 % of ICOS
+
 cells among Treg cells 
Appendix D The use of missingness graph for repeated measurements of 
multi-dimensional biomarkers 
 
 
In studies with repeated biomarker data, missing data could be either MCAR (missing completely 
at random), MAR (missing at random) or MNAR (missing not at random) [1, 2]. To represent the 
causal mechanisms underlying in each category and the corresponding assumption about their 
causal impact, Mohan et al proposed the use of graphical model using conditional 
independencies[3, 4]. The graphical models used in this case are called missingness graphs (m-
graphs). These graphs are an efficient way of presenting the properties of the missingness 
mechanisms and thus, the potential of recovering missing data. Let        be the DAG where   
is the set of observable nodes and   the set of edges in the DAG. V can be separated into      and 
     where      is the set of variables that are fully observed and      is the set of variables that 
are missing in at least one record. Let    a variable of interest and   
  the variable which is actually 
observed,      is the causal missingness mechanism of   
 . They also introduce the notion of 
recoverability [3] where under some conditions, an un biased estimate of given relation Q can be 
computed. If data D are generated by a process compatible with a graph G, a procedure that 
computes an estimator  ̂    of the relation Q converges to Q in the limit of large samples. 
The reason why it is important to determine the missingness mechanism of a variable is, because 
missing data due to MCAR, MAR or MNAR need different approaches. For instance, MCAR data 
can be listwise deleted or simple imputed. For MAR, multiple imputation can provide consistent 
estimates while pattern mixture models seem to be most  appropriate when data are MNAR [2]. 
Missingness mechanisms and their recoverability can be expressed in the following way:  
 Missing completely at random (MCAR) 
 Data are called MCAR when the probability that      is missing is independent from all other 
variables:  (   |          )   (   )                   .Thus             
        
      . Since R and    are currently observed, the joint distribution      is 
recoverable.  Figure 1 shows an example of a MCAR model where A is an auxiliary variable fully 
observed, and X the variable with missing values. In this example, based on d-separation notion, 
the missingness mechanism    is independent of all missing and fully observed variables such as 
X and A:         . The joint distribution        is then recoverable. 
 
 
 
 
 
 Missing at random (MAR) 
Data are called MAR when the missingness mechanism of     is conditionally independent of      
 (   |          )   (        )                 , thus                           
                      . Since R and  
  are currently observed, the joint distribution      is 
recoverable. Figure 2 shows an example of a simple MAR model. In this example, based on the  
d-separation notion, the missingness mechanism    and   are d-connected via  . But, as long as   
is fully observed and if conditioning on   blocks the path between   and    , then    is 
conditionally independent of   knowing           . The joint distribution        is then 
recoverable. In this case, conditioning on a variable refers to use this variable as a predictor in a 
multiple imputation model [4]. 
Figure 1:  A simple MCAR model. Nodes with dashed circle represent 
variables that would have been observed had they not missing values. 
Nodes with a star represent observed variables with missing values. 
  
 
 Missing not at random (MNAR) 
 Data are MNAR when neither MCAR nor MAR. This can occur when the probability of a 
missingness mechanism is dependant of another variable:  (   |          )   (        ). 
Figure 3 shows some typical situations where data are MNAR. Figure 3a shows the classical 
situation of MNAR data when there is a direct path between the missing variable and its 
missingness mechanism. Figure 3b shows the MNAR situation when the missing variable is d-
connected to its missingness mechanism through an unobserved variable U. Finally in figure 3c, 
MNAR holds because even when conditioning on A to get X conditionally independent of its 
missingness mechanism (MAR situation), A is not fully observed, and hence MAR does not hold. 
In MNAR situation (a) and (b), X cannot be recovered without bias while in situation (c) X could 
be recovered with some residual bias. 
 
 
 
The missingness graphs in figure 4 shows situations that can be found when analysing repeated 
immunological biomarkers. In figure 4a,        is d-connected to its missingness 
Figure 3: Three usual MNAR models. Missing data can be MNAR when there is a (un)directed path from a variable 
with missing values to its missingness mechanism (a), or through an unobserved variable U (b) or MNAR holds when 
all variables of a model are partially observed (c). Nodes with dashed circle represent variables that would have been 
observed had they not missing values. Nodes with a star represent observed variables with missing values. 
 
Figure 2: A simple MAR model. Nodes with dashed circle represent 
variables that would have been observed had they not missing values. 
Nodes with a star represent observed variables with missing values. 
mechanism        . However, when conditioning on                     ,        becomes 
conditionally independent of its missingness mechanism          
                             Thus, in this case, MAR holds and the joint distribution 
                              is recoverable using multiple imputation with                       as 
predictor. Figure 4b illustrates a MNAR situation where a variable used to block a path (used as 
predictor) is partially observed (cf figure 3c). The d-separation of        and        from their 
missingness mechanisms          and           requires to condition on                       and 
                     respectively. Since in both cases, the set of nodes used to d-separate missing 
variables and their missingness mechanisms are not fully observed, MAR does not hold. 
Therefore,        and        can only be recovered with some residual bias in Figure 4b. 
 
 
 
Figure 4:  Different missingness mechanisms found in immunological biomarkers such as MAR (a) and MNAR (b). 
Nodes with dashed circle represent variables that would have been observed had they not missing values. Nodes with 
a star represent observed variables with missing values.. 
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Appendix E Estimation of the Mean squared error (MSE) of biomarkers with 
a true effect  
 
The following tables show the mean squared of the biomarkers that have a true effect on the 
binary outcome in all scenarios tested. 
 
Table 1: Mean squared error (MSE) of biomarkers with a true effect. Parameters of the scenario 
were p=20, nvisits=4, nobs=1000 and alpha=0.02 
 MSE PC-stable MSE COPC-stable 
BM6v1 0.54 0.55 
BM11v1 0.80 0.80 
BM2v2 0.60 0.55 
BM4v2 0.28 0.11 
BM5v2 0.65 0.76 
BM11v2 0.54 0.29 
BM12v2 0.34 0.21 
BM15v2 0.69 0.45 
BM17v2 0.28 0.33 
BM18v2 0.35 0.37 
BM19v2 0.68 0.82 
BM1v4 0.47 0.14 
BM2v4 0.28 0.11 
BM11v4 0.29 0.16 
BM12v4 0.63 0.34 
BM14v4 0.77 0.33 
 
 
Table 2: Mean squared error (MSE) of biomarkers with a true effect. Parameters of the scenario 
were p=20, nvisits=4, nobs=1000 and alpha=0.2 
 
MSE PC-stable MSE COPC-stable 
BM6v1 0.54 0.55 
BM11v1 0.80 0.80 
BM2v2 0.60 0.51 
BM4v2 0.27 0.11 
BM5v2 0.74 0.71 
BM11v2 0.44 0.32 
BM12v2 0.33 0.21 
BM15v2 0.71 0.41 
BM17v2 0.27 0.41 
BM18v2 0.28 0.40 
BM19v2 0.81 0.79 
BM1v4 0.40 0.16 
BM2v4 0.23 0.09 
BM11v4 0.23 0.12 
BM12v4 0.59 0.34 
BM14v4 0.82 0.28 
 
 
Table 3: Mean squared error (MSE) of biomarkers with a true effect. Parameters of the scenario 
were p=20, nvisits=4, nobs=50 and alpha=0.02 
 
MSE PC-stable MSE COPC-stable 
BM6v1 0.54 0.55 
BM11v1 0.80 0.80 
BM2v2 0.60 0.41 
BM4v2 0.30 0.06 
BM5v2 0.81 0.62 
BM11v2 0.60 0.47 
BM12v2 0.36 0.11 
BM15v2 0.76 0.36 
BM17v2 0.42 0.29 
BM18v2 0.54 0.32 
BM19v2 0.98 0.82 
BM1v4 0.50 0.09 
BM2v4 0.38 0.13 
BM11v4 0.36 0.07 
BM12v4 0.70 0.12 
BM14v4 0.97 0.21 
 
 
  
 
 
Table 4: Mean squared error (MSE) of biomarkers with a true effect. Parameters of the scenario 
were p=20, nvisits=4, nobs=50 and alpha=0.2 
 MSE PC-stable MSE COPC-stable 
BM6v1 0.47 0.55 
BM11v1 0.77 0.80 
BM2v2 0.55 0.20 
BM4v2 0.29 0.06 
BM5v2 0.75 0.39 
BM11v2 0.52 0.15 
BM12v2 0.32 0.08 
BM15v2 0.70 0.24 
BM17v2 0.40 0.14 
BM18v2 0.48 0.16 
BM19v2 0.92 0.43 
BM1v4 0.43 0.06 
BM2v4 0.35 0.08 
BM11v4 0.31 0.05 
BM12v4 0.67 0.09 
BM14v4 0.90 0.16 
 
Table 5: Mean squared error (MSE) of biomarkers with a true effect. Parameters of the scenario 
were p=20, nvisits=6, nobs=1000 and alpha=0.02 
 MSE PC-stable MSE COPC-stable 
BM9v1 0.20 0.27 
BM11v1 0.30 0.36 
BM15v1 0.67 0.75 
BM3v2 0.31 0.21 
BM5v2 0.65 0.60 
BM11v2 0.90 0.46 
BM12v2 0.55 0.84 
BM17v2 0.41 0.54 
BM18v2 0.60 0.73 
BM2v3 0.53 0.22 
BM3v3 0.76 0.52 
BM4v3 0.22 0.15 
BM9v3 0.55 0.33 
BM19v3 0.21 0.38 
BM4v4 0.40 0.12 
BM7v4 0.42 0.52 
BM8v4 0.91 0.51 
BM9v4 0.61 0.65 
BM16v4 0.32 0.17 
BM6v5 0.60 0.31 
BM15v5 0.55 0.24 
BM7v6 0.94 0.45 
BM8v6 0.34 0.10 
 
 
Table 6: Mean squared error (MSE) of biomarkers with a true effect. Parameters of the scenario 
were p=20, nvisits=6, nobs=1000 and alpha=0.2 
 MSE PC-stable MSE COPC-stable 
BM9v1 0.23 0.27 
BM11v1 0.26 0.36 
BM15v1 0.74 0.75 
BM3v2 0.29 0.22 
BM5v2 0.54 0.64 
BM11v2 0.83 0.60 
BM12v2 0.70 0.77 
BM17v2 0.41 0.47 
BM18v2 0.44 0.70 
BM2v3 0.45 0.17 
BM3v3 0.51 0.44 
BM4v3 0.18 0.15 
BM9v3 0.49 0.25 
BM19v3 0.21 0.35 
BM4v4 0.36 0.18 
BM7v4 0.39 0.48 
BM8v4 0.85 0.46 
BM9v4 0.50 0.56 
BM16v4 0.26 0.15 
BM6v5 0.49 0.29 
BM15v5 0.40 0.21 
BM7v6 0.63 0.36 
BM8v6 0.26 0.09 
BM9v6 0.45 0.43 
 
Table 7: Mean squared error (MSE) of biomarkers with a true effect. Parameters of the scenario 
were p=20, nvisits=6, nobs=50 and alpha=0.02 
 MSE PC-
stable 
MSE COPC-
stable 
BM9v1 0.26 0.27 
BM11v1 0.35 0.36 
BM15v1 0.75 0.75 
BM3v2 0.31 0.29 
BM5v2 0.71 0.24 
BM11v2 0.95 0.47 
BM12v2 0.93 0.82 
BM17v2 0.63 0.58 
BM18v2 0.74 0.63 
BM2v3 0.55 0.34 
BM3v3 0.77 0.19 
BM4v3 0.24 0.15 
BM9v3 0.60 0.29 
BM19v3 0.53 0.22 
BM4v4 0.43 0.26 
BM7v4 0.83 0.39 
BM8v4 0.96 0.54 
BM9v4 0.68 0.36 
BM16v4 0.37 0.10 
BM6v5 0.82 0.22 
BM15v5 0.73 0.12 
BM7v6 0.97 0.25 
BM8v6 0.36 0.05 
BM9v6 0.87 0.26 
 Table 8: Mean squared error (MSE) of biomarkers with a true effect. Parameters of the scenario 
were p=20, nvisits=6, nobs=50 and alpha=0.2 
 MSE PC-stable MSE COPC-stable 
BM9v1 0.23 0.27 
BM11v1 0.30 0.36 
BM15v1 0.71 0.75 
BM3v2 0.30 0.21 
BM5v2 0.65 0.19 
BM11v2 0.84 0.36 
BM12v2 0.90 0.59 
BM17v2 0.55 0.34 
BM18v2 0.67 0.35 
BM2v3 0.53 0.13 
BM3v3 0.70 0.13 
BM4v3 0.23 0.08 
BM9v3 0.55 0.16 
BM19v3 0.49 0.20 
BM4v4 0.40 0.11 
BM7v4 0.78 0.31 
BM8v4 0.87 0.36 
BM9v4 0.67 0.31 
BM16v4 0.35 0.06 
BM6v5 0.76 0.17 
BM15v5 0.71 0.11 
BM7v6 0.93 0.26 
BM8v6 0.32 0.05 
BM9v6 0.78 0.15 
 
Appendix F Estimation of biomarkers’ median effect and PCER (per-
comparison error rate) 
 
 
Table 1: Immunological biomarkers with a PCER < 0.5% in model 2. The number following “v” in 
each biomarker’s name stands for the visit number. See additional file 3 for the complete description 
of the biomarkers. 
 
 Death Progression Toxicity 
 
Rank Biomarker  Median 
effect  
PCER  Biomarker  Median 
effect  
PCER  Biomarker  Median 
effect  
PCER  
1  BM16v2  0.81  0.0035  BM8v1  0.77  0.0031  BM7v4  0.79  0.0028  
2  BM5v1  0.81 0.0035  BM44v4  0.72  0.0036  BM8v4  0.76  0.0034  
3  BM42v3  0.80  0.0037  BM26v2  0.71  0.0041  BM16v3  0.75  0.0036  
4  BM48v1  0.86  0.0037  BM30v3  0.71  0.0041  BM26v4  0.75  0.0036  
5  BM42v2  0.80  0.0038  BM44v3  0.68  0.0042  BM7v3  0.76  0.0037  
6  BM14v4  0.79  0.0039  BM45v1  0.70  0.0047  BM9v4  0.72  0.0039  
7  BM30v4  0.80  0.0039  BM39v4  0.66  0.0049  BM39v3  0.72  0.0039  
8  BM11v4  0.83  0.0040  BM40v4  0.66  0.0049  BM32v3  0.71  0.0042  
9  BM11v1  0.76  0.0042  BM14v2  0.66  0.0050  BM30v1  0.67  0.0045  
10  BM9v4  0.81  0.0043     BM45v1  0.71  0.0046  
11  BM17v1  0.77  0.0043     BM18v3  0.71  0.0048  
12  BM11v2  0.78  0.0045        
13  BM30v1  0.76  0.0046        
14  BM31v3  0.75  0.0047        
15  BM48v3  0.78  0.0048        
16  BM25v2  0.77  0.0049        
17  BM10v4  0.77  0.0050        
 
  
Table 2: Immunological biomarkers with a PCER < 0.5% in model 3. The number following “v” in 
each biomarker’s name stands for the visit number. See additional file 3 for the complete description 
of the biomarkers. 
 
 Death Progression Toxicity 
 
Rank Biomarker  Median 
effect  
PCER  Biomarker  Median 
effect  
PCER  Biomarker  Median 
effect  
PCER  
1  BM60v3  0.87  0.0015  BM78v4  0.74  0.0024  BM96v4  0.86  0.0013  
2  BM87v1  0.83  0.0021  BM58v2  0.74  0.0025  BM87v1  0.81  0.0018  
3  BM96v4  0.84  0.0021  BM108v4  0.72  0.0025  BM8v4  0.80  0.0019  
4  BM105v4  0.83  0.0022  BM105v4  0.73  0.0026  BM9v4  0.72  0.0026  
5  BM58v2  0.81  0.0025  BM8v1  0.72  0.0028  BM7v4  0.76  0.0029  
6  BM58v4  0.80  0.0026  BM108v3  0.68  0.0031  BM57v3  0.75  0.0029  
7  BM11v4  0.81  0.0026  BM86v4  0.63  0.0031  BM88v3  0.69  0.0032  
8  BM76v3  0.80  0.0027  BM80v1  0.71  0.0031  BM59v1  0.76  0.0032  
9  BM108v4  0.80  0.0027  BM59v4  0.71  0.0032  BM62v3  0.72  0.0033  
10  BM11v1  0.78  0.0027  BM89v3  0.67  0.0032  BM93v3  0.72  0.0034  
11  BM9v4  0.80  0.0028  BM65v4  0.69  0.0032  BM65v3  0.69  0.0034  
12  BM68v4  0.77  0.0028  BM66v4  0.68  0.0032  BM89v3  0.72  0.0034  
13  BM98v4  0.78  0.0028  BM56v3  0.68  0.0033  BM7v3  0.72  0.0036  
14  BM52v1  0.78  0.0028  BM86v3  0.68  0.0033  BM63v1  0.67  0.0037  
15  BM87v2  0.81  0.0028  BM63v1  0.68  0.0034  BM69v3  0.65  0.0038  
16  BM63v4  0.77  0.0029  BM67v3  0.69  0.0035  BM11v2  0.68  0.0040  
17  BM74v4  0.77  0.0029  BM70v3  0.68  0.0036  BM104v3  0.62  0.0040  
18  BM11v2  0.78  0.0030  BM83v3  0.65  0.0039  BM6v2  0.67  0.0041  
19  BM59v1  0.76  0.0031  BM9v2  0.63  0.0039  BM80v3  0.69  0.0043  
20  BM63v3  0.77  0.0032  BM56v4  0.65  0.0041  BM103v3  0.66  0.0043  
21  BM65v3  0.75  0.0033  BM96v2  0.62  0.0043  BM10v2  0.64  0.0043  
22  BM100v3  0.76  0.0033  BM61v3  0.63  0.0044  BM98v2  0.65  0.0046  
23  BM10v4  0.77  0.0033  BM60v4  0.63  0.0045  BM96v3  0.69  0.0046  
24  BM101v3  0.75  0.0034  BM98v1  0.61  0.0046  BM83v3  0.65  0.0046  
25  BM87v3  0.69  0.0036  BM101v3  0.65  0.0046  BM75v3  0.45  0.0047  
26  BM105v2  0.71  0.0037  BM56v2  0.64  0.0047  BM91v2  0.60  0.0047  
27  BM5v1  0.76  0.0037  BM98v2  0.61  0.0047  BM72v3  0.62  0.0048  
28  BM106v4  0.75  0.0038  BM10v3  0.61  0.0047  BM90v3  0.60  0.0049  
29  BM6v3  0.70  0.0039  BM55v4  0.59  0.0048  BM56v2  0.65  0.0049  
30  BM57v3  0.69  0.0039  BM93v4  0.62  0.0050  BM9v3  0.64  0.0050  
31  BM54v4  0.71  0.0040  BM100v4  0.65  0.0050     
32  BM7v2  0.72  0.0040  BM85v2  0.61  0.0050     
33  BM79v3  0.71  0.0040        
34  BM8v2  0.63  0.0043        
35  BM70v3  0.69  0.0045        
36  BM61v2  0.74  0.0047        
37  BM65v4  0.65  0.0048        
38  BM78v4  0.75  0.0050        
39  BM63v1  0.71  0.0050        
 
